Nobody needs a crystal ball to predict the turn of the next decade as a landmark chapter in the pharmaceutical industry’s story book. The period from 2010-12 in particular will see a wave of patent expiries leave gaping holes in the balance sheets of some of the research-based industry’s bellwether companies. This Scrip analysis reviews the industry’s prospects as it squares up to one of the greatest challenges it has ever faced.
Key topics covered:
- The patent cliff: how much is at stake? - Big name products in the firing line - Evaluating the generic threat - Getting less for more? Pharmaceutical R&D vs marketing spend - Patent litigation 'a fact of life' - Case studies: Pfizer/Ranbaxy and AstraZeneca's Seroquel - Maximising the value of assets - Health technology assessment (HTA) raising the bar for line extensions - Evolving healthcare models - Buying into generics = sleeping with the enemy? Novartis/Hexal; Sanofi-Aventis/Zentiva; Daiichi Sankyo/Ranbaxy - The biosimilars political debate in the US; - Novel R&D models - Personalisation of medicine
